Background: Studies of permanent pacemaker implantation (PPI) after transcatheter
PPI is a concern especially when we are going to treat lower-risk and younger patients with TAVR. Meanwhile, the proportion of aortic stenosis patients with bicuspid aortic valve (BAV) rises up as age goes down. 2 Until recently, several studies have demonstrated feasibility and efficacy of TAVR in BAV patients. 3, 4 The reported incidence of new PPI in these BAV patients by early-or new-generation devices ranges from 13.1% to 26.7%, with potential higher incidence by the self-expanding prosthesis than balloon-expandable prosthesis. Previously identified predictors of PPI after TAVR with self-expanding devices in tricuspid morphology include pre-existing right bundle branch block (RBBB), depth of implantation, male and age >75 years. 5, 6 However, the reports of PPI post-TAVR specifically for BAV patients are lacking.
The aim of this study was to delineate possible aspects that might affect the incidence of PPI in a retrospective cohort of BAV patients treated with early-generation self-expanding devices.
| MATERIAL AND METHODS

| Study design and patient population
This study retrospectively reviewed all patients with BAV morphology who underwent TAVR in our center from May 2012 to February 2017
by one of the self-expanding prostheses, Medtronic CoreValve (Minneapolis, MI) or Venus A-Valve (Venus MedTech Inc., Hangzhou, China). 7 The choice of prosthesis was solely based on device availability at the time of intervention. Diagnosis and classification of BAV were confirmed by multi-modal imaging (ie, echocardiography and MDCT). 3 The indication for TAVR was discussed in all cases by our multidisciplinary Heart Team. Baseline clinical, echocardiographic, and angiographic characteristics, procedural and post-procedural details were collected in a dedicated prospective TAVR database according to the VARC-2 criteria. 8 The decision of PPI post-TAVR was based on Class I or II guideline recommendations as determined by 12-lead electrocardiogram. 9 All patients provided written informed consent for the procedure and data analysis for research purposes was approved by Institutional Review Board of West China Hospital.
| Procedures
All procedures were performed in a hybrid operating room. All patients received peri-procedural heparin with dose adjustments to maintain an activated clotting time of 250 to 300 seconds. The transfemoral approach was the default vascular access route but alternate access was performed when required. 10, 11 Balloon pre-and post-dilation were performed according to operator discretion. When balloon predilation was done, the valve size may be modified by balloon-sizing. 12 
| Multi-detector computed tomography acquisition
All multi-detector computed tomography (MDCT) scans were performed with a second-generation dual-source CT system (SIEMENS SOMATOM Definition Flash; SIEMENS Healthcare, Erlangen, Germany) prior to and following TAVR, as previously described. 13 Images were reconstructed at a 0.75-mm slice thickness with retrospective ECG-gating and a standard cardiac filter from early systole (0% of the R-R interval) to late diastole (90% of the R-R interval).
| Valve sizing strategy
The best method for valve sizing in BAV has yet to be defined. The usual perimeter/area at the annulus is still the mainstay way for sizing, but there have been reports and presentations taking structures above the annulus into account for sizing purposes. 14 Pre-procedural MDCT measurements were shown in Table 2 . The percentage perimeter oversizing was 13.4 ± 10.5% versus 11.9 ± 8.1%
in two groups (P = 0.51). However, when analyzing PPI rates stratified by perimeter oversizing as <10%, 10-20% and >20% (Figure 1 ), significant differences among groups were noticed (P = 0.04). Statistical significance was only seen between an oversizing greater than 20%
and an oversizing of 10-20%. When perimeter oversizing was greater than 20%, the risk of PPI was higher than an oversizing of 10-20% (OR 5.08 [1.22, 21 .07], P = 0.03). The proportion of more than mild PVL, however, was not significantly different between patients with oversizing >20% and 10-20% (11.8% vs 0%, P = 0.11). Procedural details were summarized in Table 3 . Depth of implantation was 7.9 ± 2.3 mm versus 6.3 ± 4.7 mm in two groups (P = 0.05). When stratifying it by the cut-off point of 6 mm, the proportion of patients with a depth of implantation greater than 6 mm was significantly higher in those who required PPI (82.4% vs 54.3%, P = 0.04). Figure 2 illustrated the PPI rate stratified by annulus perimeter oversizing and depth of implantation in order to demonstrate the combined effect of oversizing and depth of implantation on PPI.
The new sizing strategy incorporating supra-annular structures affected 11 patients in this cohort, leading six patients receiving a valve one size smaller than the annulus recommended. A numerically lower rate of PPI was observed after this change in sizing strategy (9.1% vs 29.0%, P = 0.27).
Subgroup analysis based on different types of BAV was performed.
The distribution of bicuspid morphology was type 0 (n = 46) and type 1 (n = 34: left-right, n = 29; left-non, n = 2; right-non, n = 3). Type 1 bicuspid patients had numerically higher rates of PPI than type 0 bicuspid patients 
| DISCUSSION
To date, this is the first study delineating possible aspects that might affect PPI after TAVR for BAV morphology using early-generation self-expanding devices. The major findings in this cohort are summarized as follows: 1) the incidence of PPI in these BAV patients was 26.3%, which is comparable with tricuspid morphology treated with early-generation self-expanding valves; 2) the incidence of PPI was significantly different when stratified by perimeter oversizing as <10%, 10-20% and >20%; 3) patients whose depth of implantation was greater than 6 mm had higher incidence of PPI.
PPI is an important complication of TAVR that may be associated with increased mortality and rehospitalization in some studies. 18 Considering the anatomical proximity of the aortic annulus to the atrial ventricular node, it is straightforward for us to think of pressing and trauma as reasons for PPI. It is well recognized that there will be higher need of PPI after self-expanding devices than balloon-expandable devices, 6 which may be related to longer stent frame design and being prone to lower implants. Thus, in some centers, patients with other risk factors of PPI at baseline are preferably treated with balloonexpandable prosthesis. 19 Can we also improve pre-procedural were associated with need for PPI. 19 As the device being deployed in LVOT, pressing on the conduction system is conceivable to induce trauma. In a finite element analysis of postoperative CT images of CoreValve stent, higher forces and more homogeneous force fields were found in patients requiring PPI after TAVR, which suggested that stronger loading of the aortic tissue might contribute to AVB. 21 Thus, it seems reasonable to avoid excessive oversizing (>20% in our cohort) during pre-procedural planning.
Although not reaching statistical significance, it seems that patients with an oversizing <10% had the highest proportion of PPI rate. This might be explained by the severe burden of calcification in this group of patients (more than 1000 mm 3 on average), which represented a challenging anatomy for optimal implantation (20.8% of patients in this subgroup ended with a depth of implantation of greater than 10 mm).
Respecting the alternated "fish-mouth" shape leaflet opening in BAV has been widely advocated recently, which usually led to smaller prosthesis size than recommended by the annulus. 20 The leaflet opening and the annulus form a "volcanic shape" across the aortic valve leaflets, an oversizing of 10% in relation to the annulus might be an oversizing of 20% in relation to the leaflet opening. This unequal oversizing ratio may result in unexpected lower implantation or greater compression to the anatomy. However, it has been suggested that there was an inverse relationship between oversizing ratio and moderate or severe PVL at discharge. 20 Selection of appropriate valve size then becomes intriguing as we need to balance the risk of PPI and PVL, especially in BAV morphology.
An attempt of subgroup analysis by different bicuspid types was also made. Although the sample size was very small in each subgroup, statistical significant risk of PPI from excessive oversizing was only shown in type 1 bicuspid patients. It has been recognized that bicuspid morphologies with three cusps would behave differently from true bicuspid valve. In a recent evaluation of a TAVR-directed BAV morphological classification, a possible relationship of PPI with orientation of leaflet fusion has been suggested. 22 Particularly in the presence of a calcified raphe, device could be pushed by the raphe toward the non-coronary cusp close to the atrioventricular node. Thus, adjusted risk assessment of PPI in different BAV morphologies awaits validation in further studies.
Another well-recognized risk factor of PPI is low depth of implantation, which is highly dependent on implantation technique. In ADVANCE-II study, optimal CoreValve system deployment and adherence to international guidelines on cardiac pacing are associated with a lower rate of new PPI after TAVR. 17 It might be trickier to control the optimal depth in BAV since prostheses with longer frame are easy to move downwards especially in cases with severe calcification or calcific raphe particularly in case of unnecessary excessive oversizing of the prosthesis, native anatomy would exert certain diving force on the device.
The prevalence of RBBB has been shown to increase with age. 23 Younger patients included in this cohort had fewer pre-existing RBBB, which might be the reason why the presence of RBBB was not significantly different in the PPI group. Being considered as a dominant predictor of PPI, RBBB has also been found to be associated with increased all-cause and cardiovascular mortality post-TAVR. 24 Thus, patients with pre-existing RBBB still need careful surveillance after the procedure.
There are certain limitations in our study. This is a single center experience with a relatively small sample size. The device used are solely early-generation self-expanding valves. Although European Society of Cardiology recommended PPI for sinus node disease, acquired AVB and bifascicular/trifascicular block, there is currently no universal indications for new PPI after TAVR. In our early experience and for patients with severe co-morbidities, we had a relatively aggressive PPI approach, which left certain bias in event incidence.
Currently, there is no unified methods for supra-annular sizing. It then becomes hard to report and compare any related measurements in this study, especially when the patient number affected by this concept is very small.
| CONCLUSIONS
Excessive perimeter oversizing (ie, a perimeter oversizing greater than 20%) in relation to aortic annulus and depth of implantation greater than 6 mm should be avoided to improve PPI post-TAVR for BAV patients receiving self-expanding devices.
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FIGURE 3
Odds ratio of perimeter oversizing and depth of implantation in different bicuspid morphologies for permanent pacemaker implantation after transcatheter aortic valve replacement
